AHP Interview Study
An interview study is underway to understand patient experiences with acute hepatic porphyria.
We are looking for individuals ages 15 and over in the United States or Canada who have acute hepatic porphyria (AHP).
GATEWAY Phase 2 Study: Short-Term Clinical Trial Opportunity for Adults with EPP
The GATEWAY Phase 2 Study is enrolling adults with Erythropoietic Protoporphyria (EPP) to test a potential new treatment.
APOLLO Study for EPP & XLP
A clinical trial evaluating Bitopertin, an investigational oral medication for individuals with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP). The study aims to assess whether Bitopertin can reduce protoporphyrin IX levels and potentially lessen symptoms from sun exposure.